Join
Live feed
·
PRReleasevia Quantisnow
Climb Bio Inc. logo

Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

ByQuantisnow·Wall Street's wire, on your screen.
CLYM· Climb Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLYM (Climb Bio Inc.) and more on Quantisnow.